- Home
- VKTX vs KNSA Comparison
VKTX vs KNSA Comparison
Compare VKTX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VKTX | KNSA |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.9B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VKTX | KNSA |
|---|---|---|
| Price | $34.85 | $62.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $95.86 | $60.86 |
| AVG Volume (30 Days) | ★ 2.4M | 905.3K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | N/A | $17.87 |
| P/E Ratio | ★ N/A | $233.52 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $22.96 | $26.51 |
| 52 Week High | $43.15 | $67.53 |
Technical Indicators
Market Signals| Indicator | VKTX | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 55.14 |
| Support Level | $34.03 | $60.07 |
| Resistance Level | $36.77 | $67.53 |
| Average True Range (ATR) | 2.05 | 2.60 |
| MACD | -0.66 | -0.45 |
| Stochastic Oscillator | 3.75 | 33.82 |
Price Performance
Historical ComparisonAbout VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.